|
Corporate strategy
.................................................................................
Objectives
Our goal is to have a meaningful impact on skin disease and particularly skin cancers: the world's most common cancers, by delivering breakthrough solutions to patients.
The primary strategic objective is to develop PEP005 (ingenol mebutate) in two topical products to address the significant market opportunity for a rapidly acting, simple to use and cosmetically attractive non-surgical treatment for AK and BCC. Beyond this, Peplin has a strategy of building its business with complimentary products focused in medical dermatology.
Strategies to achieve objectives
Operational strategy
Our objective is to build a specialty pharmaceutical company focused on the development and commercialization of products for selected medical dermatology markets in the United States, Australia and New Zealand. Key aspects of our strategy include:
- successfully developing PEP005 (ingenol mebutate) Gel for AK;
- successfully developing PEP005 (ingenol mebutate) Gel l for BCC and pursuing additional dermatology indications;
- driving the adoption of our products through a direct sales and marketing effort; and;
- acquiring or in-licensing complementary drug candidates within our area of commercial focus.
Commercial strategy
We own patents and have filed applications that relate to the use of PEP005 (ingenol mebutate) and related molecules and pharmaceutical compositions of those molecules from plants in the genus Euphorbiaceae in the treatment of cancers, AK, pre-cancers and certain other diseases in the United States, Australia, New Zealand, as well as several other markets around the world, including in the European Union. In addition, we have filed patents which protect certain aspects of our product candidate formulations. We plan to develop a direct sales and marketing organization to commercialize and market PEP005 (ingenol mebutate) Gell for AK to the dermatology community if it receives regulatory approval. Initially, we anticipate that Peplin sales representatives will target high prescribing dermatologists in the United States, and dermatologists and other clinicians that treat AK in Australia and New Zealand. As a result, we believe a relatively modest sales organization can effectively penetrate this market.
Corporate development strategy
Peplin has established a capability in the development of therapeutic products. Peplin will seek to expand and leverage that capability through a focused strategy of enhancing its pipeline of product candidates particularly in dermatology.
|
|
